Telacebec (Q203), a New Antituberculosis Agent

N Engl J Med. 2020 Mar 26;382(13):1280-1281. doi: 10.1056/NEJMc1913327.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Antitubercular Agents / administration & dosage*
  • Antitubercular Agents / adverse effects
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Ethambutol / administration & dosage
  • Humans
  • Imidazoles / administration & dosage*
  • Imidazoles / adverse effects
  • Isoniazid / administration & dosage
  • Mycobacterium tuberculosis / drug effects*
  • Piperidines / administration & dosage*
  • Piperidines / adverse effects
  • Pyrazinamide / administration & dosage
  • Pyridines / administration & dosage*
  • Pyridines / adverse effects
  • Rifampin / administration & dosage
  • Tuberculosis, Pulmonary / drug therapy*

Substances

  • Antitubercular Agents
  • Imidazoles
  • Piperidines
  • Pyridines
  • Pyrazinamide
  • telacebec
  • Ethambutol
  • Isoniazid
  • Rifampin